MediciNova (MediciNova) Days Sales Outstanding

: 0.00 (As of Dec. 2023)

View and export this data going back to 2006. Start your Free Trial

MediciNova's average Accounts Receivable for the three months ended in Dec. 2023 was $1.00 Mil. MediciNova's Revenue for the three months ended in Dec. 2023 was $0.00 Mil.

The historical rank and industry rank for MediciNova's Days Sales Outstanding or its related term are showing as below:

MNOV' s Days Sales Outstanding Range Over the Past 10 Years
Min: 0 Med: 0 Max: 365
Current: 365

During the past 13 years, MediciNova's highest Days Sales Outstanding was 365.00. The lowest was 0.00. And the median was 0.00.

MNOV's Days Sales Outstanding is ranked worse than
90.43% of 888 companies
in the Biotechnology industry
Industry Median: 72.335 vs MNOV: 365.00

MediciNova's Days Sales Outstanding stayed the same from Dec. 2022 (0.00) to Dec. 2023 (0.00).

MediciNova Days Sales Outstanding Historical Data

The historical data trend for MediciNova's Days Sales Outstanding can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

* Premium members only.

MediciNova Annual Data

Trend

Dec14

Dec15

Dec16

Dec17

Dec18

Dec19

Dec20

Dec21

Dec22

Dec23

Days Sales Outstanding

Get a 7-Day Free Trial

MediciNova Quarterly Data
	Mar19	Jun19	Sep19	Dec19	Mar20	Jun20	Sep20	Dec20	Mar21	Jun21	Sep21	Dec21	Mar22	Jun22	Sep22	Dec22	Mar23	Jun23	Sep23	Dec23
Days Sales Outstanding	Get a 7-Day Free Trial															-	-	-	91.25	-

Competitive Comparison

For the Biotechnology subindustry, MediciNova's Days Sales Outstanding, along with its competitors' market caps and Days Sales Outstanding data, can be viewed below:

* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.

MediciNova Days Sales Outstanding Distribution

For the Biotechnology industry and Healthcare sector, MediciNova's Days Sales Outstanding distribution charts can be found below:

* The bar in red indicates where MediciNova's Days Sales Outstanding falls into.

MediciNova Days Sales Outstanding Calculation

Days Sales Outstanding measures the average number of days that a company takes to collect revenue after a sale has been made. It is a financial ratio that illustrates how well a company's Accounts Receivable are being managed.

Accounts Receivable can be measured by Days Sales Outstanding.

MediciNova's Days Sales Outstanding for the fiscal year that ended in Dec. 2023 is calculated as

	Days Sales Outstanding (A: Dec. 2023 )
=	Average Accounts Receivable					/	Revenue	*	Days in Period
=	( (Accounts Receivable (A: Dec. 2022 )	+	Accounts Receivable (A: Dec. 2023 ))	/	count )	/	Revenue (A: Dec. 2023 )	*	Days in Period
=	( (0	+	0)	/	1 )	/	1	*	365
=	0					/	1	*	365
=	0.00

MediciNova's Days Sales Outstanding for the quarter that ended in Dec. 2023 is calculated as:

	Days Sales Outstanding (Q: Dec. 2023 )
=	Average Accounts Receivable					/	Revenue	*	Days in Period
=	( (Accounts Receivable (A: Sep. 2023 )	+	Accounts Receivable (A: Dec. 2023 ))	/	count )	/	Revenue (A: Dec. 2023 )	*	Days in Period
=	( (1	+	0)	/	1 )	/	0	*	365 / 4
=	1					/	0	*	365 / 4
=	N/A

MediciNova (NAS:MNOV) Days Sales Outstanding Explanation

For retailers, when we compare Days Sales Outstanding, it is important to compare the same period in the previous years.

MediciNova Days Sales Outstanding Related Terms

Thank you for viewing the detailed overview of MediciNova's Days Sales Outstanding provided by GuruFocus.com. Please click on the following links to see related term pages.

MediciNova (MediciNova) Business Description

Industry

GURUFOCUS.COM » STOCK LIST » Healthcare » Biotechnology » MediciNova Inc (NAS:MNOV) » Definitions » Days Sales Outstanding

Comparable Companies

Traded in Other Exchanges

4875:Japan

Address

4275 Executive Square, Suite 300, La Jolla, CA, USA, 92037

Website

https://www.medicinova.com

MediciNova Inc is a biopharmaceutical company. The company acquires and develops small-molecule therapeutics for the treatment of diseases with unmet medical needs with a specific focus on the U.S. market. Its products portfolio includes therapeutics such as MN-001, MN-166, MN-221 etc. The firm's current strategy is to focus its development activities on therapeutics for neurological disorders and fibrotic diseases.

Executives

Nicole Lemerond	director	3 MURRAY HILL ROAD, SCARSDALE NY 10583
Hideki Nagao	director	4350 LA JOLLA VILLAGE DRIVE, SUITE 950, SAN DIEGO CA 92122
Jason J Kruger	officer: Chief Financial Officer	4275 EXECUTIVE SQUARE, SUITE 300, LA JOLLA CA 92037
Douglas Paulin	officer: Chief Financial Officer	4275 EXECUTIVE SQUARE, SUITE 300, LA JOLLA CA 92037
Gaeta Federico C.a.	officer: Chief Scientific Officer	4275 EXECUTIVE SQUARE, SUITE 300, LA JOLLA CA 92037
3d Investment Partners Pte. Ltd.	10 percent owner	250 NORTH BRIDGE ROAD, #13-01 RAFFLES CITY TOWER, SINGAPORE U0 179101
3d Opportunity Master Fund	10 percent owner	C/O MAPLES CORPORATE SERVICES LIMITED, PO BOX 309, UGLAND HOUSE, GRAND CAYMAN E9 KY1-1104
Carolyn Beaver	director	3595 JOHN HOPKINS COURT, SAN DIEGO CA 92121
Stepanow Edward C Jr.	officer: Chief Financial Officer	4275 EXECUTIVE SQUARE SUITE 300, LA JOLLA CA 92037
Kazuko Matsuda	officer: Chief Medical Officer	C/O MEDICINOVA, INC., 4275 EXECUTIVE SQUARE, SUITE 650, LA JOLLA CA 92037
Yuichi Iwaki	director	C/O MEDICINOVA, INC., 4275 EXECUTIVE SQUARE, SUITE 650, LA JOLLA CA 92037
Carla Reyes	officer: Chief Financial Officer	4275 EXECUTIVE SQUARE, SUITE 300, LA JOLLA CA 92037
Yoshio Ishizaka	director	4275 EXECUTIVE SQUARE, SUITE 650, LA JOLLA CA 92037
Yutaka Kobayashi	director	4275 EXECUTIVE SQUARE, SUITE 650, LA JOLLA CA 92037
Geoffrey Obrien	officer: Vice President	4275 EXECUTIVE SQUARE, SUITE 650, LA JOLLA CA 92037